The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
An open-label, single-arm, multicenter, phase II study of RC48-ADC to evaluate the efficacy and safety of subjects with HER2 overexpressing locally advanced or metastatic urothelial cancer (RC48-C009).
 
Xinan Sheng
No Relationships to Disclose
 
Zhisong He
No Relationships to Disclose
 
Weiqing Han
No Relationships to Disclose
 
Ai-Ping Zhou
Consulting or Advisory Role - Merck Serono; Pfizer; Roche
Travel, Accommodations, Expenses - Merck Serono; Pfizer; Roche
 
Hong Luo
No Relationships to Disclose
 
Yanxia Shi
No Relationships to Disclose
 
Changlu Hu
No Relationships to Disclose
 
Ziling Liu
No Relationships to Disclose
 
Hongqian Guo
No Relationships to Disclose
 
Xin Yao
No Relationships to Disclose
 
Benkang Shi
No Relationships to Disclose
 
Jiyan Liu
No Relationships to Disclose
 
Zhigang Ji
No Relationships to Disclose
 
Jianming Guo
No Relationships to Disclose
 
Yi Hu
No Relationships to Disclose
 
Shi Ying Yu
No Relationships to Disclose
 
Guohua Yu
No Relationships to Disclose
 
Jianming Ying
No Relationships to Disclose
 
Jianmin Fang
Employment - RemeGen; RemeGen (I)
Leadership - RemeGen
Stock and Other Ownership Interests - RemeGen
Research Funding - RemeGen
Patents, Royalties, Other Intellectual Property - RemeGen
 
Jun Guo
Consulting or Advisory Role - Bayer; MSD; Novartis; Oriengene; Pfizer; Roche; Shanghai Junshi BioSciences; Simcere